Project BioShield

reportActive / Technical Report | Accession Number: ADA477928 | Open PDF

Abstract:

Many potential biological terrorism agents lack available countermeasures. President Bush proposed Project BioShield to address this need. The 108th Congress considered this proposal in S. 15 Gregg, S. 1504 Gregg, and H.R. 2122 Tauzin. President Bush signed S. 15 into law on July 21, 2004 The Project BioShield Act of 2004, P.L. 108-276. The main provisions of this law include the following 1 relaxing procedures for bioterrorism-related procurement, hiring, and awarding research grants 2 guaranteeing a federal government market for new biomedical countermeasures and 3 permitting emergency use of unapproved countermeasures. Project BioShield countermeasure procurement is funded by the Department of Homeland Security Appropriations Act, 2004 P.L. 108-90 which advance-appropriated 5.593 billion for FY2004-FY2013. Additional measures to encourage the development of countermeasures are being considered by the 109th Congress in S. 3 Gregg and S. 975 Lieberman. This report will be updated in response to legislative developments.

Author(s):
Gottron, Frank
Author Organization(s):
LIBRARY OF CONGRESS WASHINGTON DC CONGRESSIONAL RESEARCH SERVICE
Descriptive Note:
Congressional rept.
Supplementary Note:
CRS Report for Congress.
Pagination:
0007

Security Markings

DOCUMENT & CONTEXTUAL SUMMARY

Distribution:
Approved For Public Release
Distribution Statement:
Approved For Public Release; Distribution Is Unlimited.

RECORD

Collection: TR
Identifying Numbers
Report Number(s):
CRS-RS21507
Monitor Series:
CRS/DC
 Subject Terms
Joint Capability Areas:
JCA_1.4.1_Force Health Protection; JCA_1.4_Force Support; JCA_6.4.1_Secure Information Exchange; JCA_6_Net Centric; JCA_1_Force Support; JCA_4.2.3_Manage Global Supplier Networks; JCA_4.2_Supply; JCA_5_Command and Control; JCA_6.4_Information Assurance; JCA_1.2_Force Preparation; JCA_8_Building Partnerships; JCA_3.2_Engagement; JCA_3_Force Application; JCA_3.2.2_Non-Kinetic Means; JCA_5.3_Planning; JCA_8.2_Shape
Modernization Areas:
Biotechnology
Communities of Interest:
No COI(s) Identified
Descriptor(s):
*UNITED STATES GOVERNMENT, *GOVERNMENT PROCUREMENT, *THERAPY, *BIOLOGICAL WARFARE AGENTS, *COUNTERMEASURES, *BIOTERRORISM, *LEGISLATION, POLICIES, ANTIVIRAL AGENTS, PREVENTIVE MEDICINE, TULAREMIA, VARIOLA VIRUS, BOTULISM, GRANTS, BACILLUS ANTHRACIS, PLAGUES, ANTIBIOTICS, FEDERAL BUDGETS, VACCINES, COUNTERTERRORISM, ANTHRAX, HEMORRHAGIC FEVERS, BIOTECHNOLOGY, DIAGNOSIS(MEDICINE), CONTRACTS
Field(s)/Group(s):
Government and Political Science, Sociology and Law, Medicine and Medical Research, Pharmacology, Chemical, Biological and Radiological Warfare
Keyword(s):
*PROJECT BIOSHIELD, RESEARCH AND DEVELOPMENT, COMMERCIALIZATION, S 15 LEGISLATION, HR 2122 LEGISLATION, S 1504 LEGISLATION, EXPEDITED PEER REVIEW, MARKET GUARANTEES, EXEMPTIONS TO FDA APPROVAL PROCESS, POLICY OPTIONS, INDEMNIFICATION, ECONOMIC INCENTIVES, S 3 LEGISLATION, S 975 LEGISLATION
Report Date:
2005 Jun 10
Creation Date:
2008 Mar 26